共 311 条
[1]
Rosenthal E(2007)Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) J Viral Hepat 14 183-188
[2]
Pialoux G(2001)Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection Clin Infect Dis 32 492-497
[3]
Bernard N(2003)A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 257-265
[4]
Pradier C(2009)Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 407-413
[5]
Rey D(2011)Hepatitis C treatment response kinetics and impact of baseline predictors J Viral Hepat 18 400-407
[6]
Bentata M(2008)Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 634-651
[7]
Michelet C(2011)“Real-Life” comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus Hepatology 53 1405-1406
[8]
Pol S(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355
[9]
Perronne C(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965
[10]
Cacoub P(2007)Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis J Viral Hepat 14 239-248